Harmony Biosciences officer plans $1.5M sale

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. (HRMY) officer Kumar Budur filed a notice of proposed resale of 35,852 shares of common stock under Rule 144, to be sold through Morgan Stanley Smith Barney LLC, with an indicated market value of $1,532,314.48 and based on 58,236,393 shares outstanding on NASDAQ as of September 18, 2026.

The shares are to be sold on September 18, 2026 following an exercise of stock options for cash. Over the prior three months, Budur reported multiple Rule 10b5-1 plan sales of HRMY common stock, including blocks of 800, 1,800, 5,500, 22,954, and 5,500 shares on various September 2026 dates.

Key Figures

Shares to be sold under Rule 144: 35,852 shares Market value of securities to be sold: $1,532,314.48 Shares outstanding: 58,236,393 shares +4 more

7 metrics

Shares to be sold under Rule 144 35,852 shares Planned resale of Harmony Biosciences common stock on September 18, 2026

Market value of securities to be sold $1,532,314.48 Indicated value of 35,852 shares of HRMY common stock

Shares outstanding 58,236,393 shares Harmony Biosciences common stock outstanding as of September 18, 2026

10b5-1 sale on September 17, 2026 800 shares for $34,400.00 Rule 10b5-1 sale of HRMY common stock by Kumar Budur

10b5-1 sale on September 16, 2026 1,800 shares for $77,426.28 Rule 10b5-1 sale of HRMY common stock by Kumar Budur

Largest 10b5-1 sale on September 8, 2026 22,954 shares for $989,349.63 Rule 10b5-1 sale of HRMY common stock by Kumar Budur

Additional 10b5-1 sales on September 4 and 8, 2026 5,500 shares for $230,911.45; 5,500 shares for $232,908.65 Rule 10b5-1 sales of HRMY common stock by Kumar Budur

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options, Form 144, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for KUMAR BUDUR 630 W Germantown Pike..."

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/18/2026 | Exercise of Stock Options | Issuer..."

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

common stock financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services..."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Harmony Biosciences (HRMY)?

It discloses that officer Kumar Budur plans to sell 35,852 shares of Harmony Biosciences common stock under Rule 144, following an exercise of stock options for cash, with an indicated market value of $1,532,314.48 on NASDAQ as of September 18, 2026.

How many Harmony Biosciences (HRMY) shares are proposed to be sold under Rule 144?

The notice covers a proposed sale of 35,852 shares of HRMY common stock. These shares are tied to an exercise of stock options and are intended to be sold on September 18, 2026 for cash through Morgan Stanley Smith Barney LLC.

What recent 10b5-1 sales has the Harmony Biosciences (HRMY) officer reported?

Kumar Budur reported Rule 10b5-1 plan sales of HRMY common stock including 800 shares for $34,400 on September 17, 2026; 1,800 shares for $77,426.28 on September 16, 2026; and additional blocks of 5,500, 22,954, and 5,500 shares earlier in September 2026.

What was the largest single 10b5-1 sale amount disclosed for HRMY shares?

The largest single 10b5-1 transaction disclosed is a sale of 22,954 shares of Harmony Biosciences common stock for $989,349.63 on September 8, 2026, executed under a Rule 10b5-1 trading plan for Kumar Budur.

How many Harmony Biosciences (HRMY) shares were outstanding in this Form 144?

The filing lists 58,236,393 shares outstanding of Harmony Biosciences common stock as of September 18, 2026. This figure serves as context for the proposed 35,852-share Rule 144 resale by officer Kumar Budur.

Who is the broker handling the planned Harmony Biosciences (HRMY) Rule 144 sale?

The proposed Rule 144 sale of 35,852 HRMY shares for officer Kumar Budur is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, as stated in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:20 PM Accepted by SEC EDGAR 09/18/2026 - 04:19 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002009762
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	HARMONY BIOSCIENCES HOLDINGS, INC.
SEC File Number	001-39450
Address of Issuer	630 W Germantown Pike, Suite 215 Plymouth Meeting PENNSYLVANIA 19462
Phone	(484)-539-9800
Name of Person for Whose Account the Securities are To Be Sold	KUMAR BUDUR
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	35852	1532314.48	58236393	09/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/18/2026	Exercise of Stock Options	Issuer			35852	09/18/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KUMAR BUDUR 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	09/17/2026	800	34400.00
10b5-1 Sales for KUMAR BUDUR 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	09/16/2026	1800	77426.28
10b5-1 Sales for KUMAR BUDUR 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	09/08/2026	5500	232908.65
10b5-1 Sales for KUMAR BUDUR 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	09/08/2026	22954	989349.63
10b5-1 Sales for KUMAR BUDUR 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	09/04/2026	5500	230911.45

144: Remarks and Signature

Remarks
Date of Notice	09/18/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kumar Budur
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)